SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005; 115: 11828.
  • 2
    Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984; 27: 96875.
  • 3
    Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? [review]. Arthritis Rheum 1997; 40: 518.
  • 4
    Danks L, Sabokbar A, Gundle R, Athanasou NA. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 2002; 61: 91621.
  • 5
    Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 25969.
  • 6
    Tsuboi H, Udagawa N, Hashimoto J, Yoshikawa H, Takahashi N, Ochi T. Nurse-like cells from patients with rheumatoid arthritis support the survival of osteoclast precursors via macrophage colony-stimulating factor production. Arthritis Rheum 2005; 52: 381928.
  • 7
    Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 10415.
  • 8
    Chikanza IC, Kingsley G, Panayi GS. Peripheral blood and synovial fluid monocyte expression of interleukin 1α and 1β during active rheumatoid arthritis. J Rheumatol 1995; 22: 6006.
  • 9
    Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988; 168: 157386.
  • 10
    Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 7848.
  • 11
    Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397440.
  • 12
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 13
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 144350.
  • 14
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 2637.
  • 15
    Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992; 65: 239.
  • 16
    Cope AP, Maini RN. Soluble tumor necrosis factor receptors in arthritis. J Rheumatol 1995; 22: 3824.
  • 17
    Brennan FM, Chantry D, Turner M, Foxwell B, Maini R, Feldmann M. Detection of transforming growth factor-β in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 1990; 81: 27885.
  • 18
    Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996; 39: 38695.
  • 19
    Husby G, Bankhurst AD, Williams RC Jr. Immunohistochemical localization of prostaglandin E in rheumatoid synovial tissues. Arthritis Rheum 1977; 20: 78591.
  • 20
    Sturge RA, Yates DB, Gordon D, Franco M, Paul W, Bray A, et al. Prostaglandin production in arthritis. Ann Rheum Dis 1978; 37: 31520.
  • 21
    Kunisch E, Jansen A, Kojima F, Loffler I, Kapoor M, Kawai S, et al. Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-α on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol 2009; 183: 132836.
  • 22
    Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006; 6: 38394.
  • 23
    Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med 1994; 180: 236570.
  • 24
    Van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181: 7759.
  • 25
    Alvarellos A, Lipsky PE, Jasin HE. Prostaglandin E2 modulation of rheumatoid factor synthesis. Arthritis Rheum 1988; 31: 147380.
  • 26
    Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Boumpas DT. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J Immunol 1992; 148: 284552.
  • 27
    Zurier RB, Quagliata F. Effect of prostaglandin E1 on adjuvant arthritis. Nature 1971; 234: 3045.
  • 28
    Zurier RB, Damjanov I, Sayadoff DM, Rothfield NF. Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis. Arthritis Rheum 1977; 20: 144956.
  • 29
    Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109: 88393.
  • 30
    Shi J, Johansson J, Woodling NS, Wang Q, Montine TJ, Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010; 184: 720718.
  • 31
    Moriuchi-Murakami E, Yamada H, Ishii O, Kikukawa T, Igarashi R. Treatment of established collagen induced arthritis with prostaglandin E1 incorporated in lipid microspheres. J Rheumatol 2000; 27: 238996.
  • 32
    Nozaki T, Takahashi K, Ishii O, Endo S, Hioki K, Mori T, et al. Development of an ex vivo cellular model of rheumatoid arthritis: critical role of CD14-positive monocyte/macrophages in the development of pannus tissue. Arthritis Rheum 2007; 56: 287585.
  • 33
    Yamamoto H, Maruyama T, Sakata K, Koketsu M, Kobayashi M, Yoshida H, et al. Novel four selective agonists for prostaglandin E receptor subtypes. Prostaglandins Other Lipid Mediat 1999; 59: 150.
  • 34
    Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000; 141: 15549.
  • 35
    Miyamoto M, Ito H, Mukai S, Kobayashi T, Yamamoto H, Kobayashi M, et al. Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation. Osteoarthritis Cartilage 2003; 11: 64452.
  • 36
    Jones RL, Qian YM, Chan KM, Yim AP. Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol 1998; 125: 128896.
  • 37
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 38
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 39
    Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 96475.
  • 40
    Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995; 38: 15818.
  • 41
    Van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1097106.
  • 42
    Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004; 199: 24451.
  • 43
    Bromley M, Woolley DE. Histopathology of the rheumatoid lesion: identification of cell types at sites of cartilage erosion. Arthritis Rheum 1984; 27: 85763.
  • 44
    Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 16396.
  • 45
    Di Battista JA, Martel-Pelletier J, Pelletier J. Suppression of tumor necrosis factor (TNF-α) gene expression by prostaglandin E2: role of early growth response protein-1 (Egr-1). Osteoarthritis Cartilage 1999; 7: 3958.
  • 46
    Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 4414754.
  • 47
    Gomez PF, Pillinger MH, Attur M, Marjanovic N, Dave M, Park J, et al. Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-κB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol 2005; 175: 692430.
  • 48
    Faour WH, Alaaeddine N, Mancini A, He QW, Jovanovic D, Di Battista JA. Early growth response factor-1 mediates prostaglandin E2-dependent transcriptional suppression of cytokine-induced tumor necrosis factor-α gene expression in human macrophages and rheumatoid arthritis-affected synovial fibroblasts. J Biol Chem 2005; 280: 953646.
  • 49
    Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003; 278: 121516.
  • 50
    Minami M, Shimizu K, Okamoto Y, Folco E, Ilasaca ML, Feinberg MW, et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-κB1 and attenuates macrophage activation. J Biol Chem 2008; 283: 9692703.
  • 51
    Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 23355.
  • 52
    Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003; 171: 60809.
  • 53
    Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 106671.
  • 54
    Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 212.
  • 55
    Hinz B, Brune K, Pahl A. Prostaglandin E2 upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2000; 272: 7448.
  • 56
    Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 27586.
  • 57
    Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 17.
  • 58
    Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000; 275: 1981923.
  • 59
    Sakuma Y, Tanaka K, Suda M, Komatsu Y, Yasoda A, Miura M, et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun 2000; 68: 681925.
  • 60
    Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000; 15: 21827.
  • 61
    Lader CS, Flanagan AM. Prostaglandin E2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998; 139: 315764.
  • 62
    Take I, Kobayashi Y, Yamamoto Y, Tsuboi H, Ochi T, Uematsu S, et al. Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 2005; 146: 520414.
  • 63
    Graham S, Gamie Z, Polyzois I, Narvani AA, Tzafetta K, Tsiridis E, et al. Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: in vivo and in vitro evidence. Expert Opin Investig Drugs 2009; 18: 74666.
  • 64
    Nakagawa K, Imai Y, Ohta Y, Takaoka K. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007; 41: 5438.
  • 65
    Tanaka M, Sakai A, Uchida S, Tanaka S, Nagashima M, Katayama T, et al. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004; 34: 9408.
  • 66
    Clarris BJ. Morphological effects of prostaglandins E1, E2 and F2α on fibroblast-like cultures of human synovial cells. Experientia 1982; 38: 3501.
  • 67
    Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997; 122: 21724.